BioSpace News Archive

MaxCyte, Inc., is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022.

Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the fourth quarter and full year ended December 31, 2021.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it has commenced a global offering of $500 million of ordinary shares, which may be represented by American Depository Shares.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of Directors.

Coherus BioSciences, Inc. today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City.

HeartPoint Global announced another major milestone in the ongoing pre-clinical trials of the HeartPoint Global Implant System, a first-of-its-kind patented, adjustable system which focuses on treating devastating left heart diseases, congestive heart failure, and structural pulmonary hypertension.

Neurotechnology Powerhouse NeuroVigil announced at the New Technology & Mental Health Conference keynote during Dubai’s World Expo that it has recruited senior captains of industry, government and academia to scale operations leading up to the launch of its newest non-invasive iBrain™ brain monitor, designated by the New York Times as “an innovation which will change your tomorrow”.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the year ended December 31, 2021 and provided a business update.

March 22, 2022, Shanghai Fosun Pharmaceutical Co., Ltd., a global innovation-driven pharmaceutical and healthcare industry group in China, announced its annual results for the year of 2021, together with its 2021 Corporate Social Responsibility report.